SAN DIEGO, CA / ACCESS Newswire / January 21, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing ...

The approval of this accelerated pathway not only demonstrates the FDA’s full recognition of the quality, safety, and efficacy of the Phase 1 clinical data of hNPC01 in China, but also will ...

Health care is undergoing an important and well-needed shift from a one-size-fits-all approach to more personalized, precise, patient-focused care. A similar approach needs to be implemented at scale ...

Adaptive clinical trial design represents a modern approach to evaluating healthcare interventions that allows pre‐specified modifications based on accumulating data. This flexible methodology ...

Improved Cancer-Specific Risk Stratification by the Lymph Node Ratio-Based Nomogram: A Potential Role in Guiding Postoperative Management Decisions for Oral Cavity Carcinoma We propose a novel ...

The FDA’s new draft guidance on Bayesian methodology signals a shift toward more flexible, data-driven clinical trial designs, enabling sponsors to use prior data and adaptive approaches to improve ...

antiviral effectiveness of the drug in patients. The overall clinical trial will enroll approximately 80 patients. “This is an important milestone towards filing of the clinical trial application and ...

In this free webinar, understand the key benefits of master protocols. Attendees will identify the key challenges of master protocols and strategies to address them. The featured speakers will discuss ...

Imfinzi with monalizumab and ceralasertib showed promising long-term benefits in advanced NSCLC, but no other combinations significantly improved results. Long-term benefits were improved in some ...

SHELTON, CT / ACCESS Newswire / July 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of ...